Disruptive Innovation of the Drug Discovery and Development

Continuous innovation is one of the pharmaceutical industry’s most defining characteristics. New medications can be crucial for maintaining the quality of human life, and may even affect its duration.1

Broadly speaking, there are three factors that have the potential to limit how innovative the drug development process can be. First, technical limitations make the development of innovative drugs more risky, as the underlying science may not yet be fully understood, or more broadly. Second, financial constraints cause individual drug makers to bear substantial technical risk, which can lead them to favor safer investments that tend to be less innovative. Finally, regulatory forces may make it more difficult for groundbreaking medicines to win approval due to uncertainty about new ways to combat disease. If these factors can be addressed, the argument for investing in innovative new drugs will become much more straightforward.2

The talk will be focused on the innovative approach and development of pharma companies.

Special focus will be given to new way of conducting bionalytical studies.

1.Petrova, E.. “Chapter 2 Innovation in the Pharmaceutical Industry : The Process of Drug Discovery and Development.” (2017).

2.Promoting Innovation in Drug Development, Nicholas Downing